Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antiplatelet drugs in the treatment of acute coronary syndromes: Focus on cyclooxygenase inhibitors
Autore:
Cruz-Fernandez, JM;
Indirizzi:
Hosp Univ Virgen de Macarena, Serv Cardiol, Seville 41071, Spain Hosp UnivVirgen de Macarena Seville Spain 41071 l, Seville 41071, Spain Univ Seville, Sch Med, Dept Med Cardiol, Seville 41071, Spain Univ Seville Seville Spain 41071 Dept Med Cardiol, Seville 41071, Spain
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: I, volume: 3, anno: 2001,
pagine: I23 - I30
SICI:
1520-765X(200108)3:I<I23:ADITTO>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; PLATELET-AGGREGATION; MULTICENTER TRIAL; ASPIRIN; TRIFLUSAL; ACID; INFLAMMATION; PHARMACOLOGY; DERIVATIVES;
Keywords:
acute coronary syndromes; antiplatelet agents; aspirin; cyclooxygenase inhibitors; triflusal;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Cruz-Fernandez, JM Avda Repub Argentina 15,5-A, Seville 41011, Spain AvdaRepub Argentina 15,5-A Seville Spain 41011 Spain
Citazione:
J.M. Cruz-Fernandez, "Antiplatelet drugs in the treatment of acute coronary syndromes: Focus on cyclooxygenase inhibitors", EUR H J SUP, 3(I), 2001, pp. I23-I30

Abstract

Despite its widespread use and documented efficacy in the treatment of acute coronary syndromes, aspirin has some limitations and the search for moreeffective and safer alternatives continues. This article analyses sonic current aspects of the treatment of these syndromes with the cyclooxygenase inhibitor triflusal. Triflusal inhibits platelet cyclooxygenase activity but does not interferesignificantly with endothelial synthesis of prostacyclin via the cyclooxygenase-2 pathway. This drug also increases nitric oxide synthesis by neutrophils, and decreases the activity of nuclear transcription factor NF-kappaB more than aspirin does. Moreover, triflusal inactivates intraplatelet phosphodiesterase and potentiates the antiaggregant effect of cAMP and cGMP, since it interferes with the degradation of these compounds. These pharmacological differences make triflusal potentially more effective and safer than aspirin. For unstable angina or non-Q-wave myocardial infarction, triflusal is as effective as aspirin. In a multicentre study of more than 2000 patients withacute myocardial infarction, triflusal was as effective as aspirin, and had a better safety profile, significantly decreasing (> 60%) the incidence of cerebrovascular accidents. The patients likely to benefit most from treatment with triflusal were those receiving fibrinolytic treatment, patients older than 65 years, and those receiving concomitant treatment with angiotensin-converting enzyme inhibitors. Triflusal is currently a valid alternative to aspirin for unstable angina,and for acute myocardial infarction it is the only alternative drug shown to be as effective as aspirin but safer. (C) 2001 The European Society of Cardiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 02:06:13